Arjan Kortholt

Dr. Arjan Kortholt

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAngélica María Sabogal-Guáqueta
Angélica María Sabogal-Guáqueta
AMAlejandro Marmolejo-Garza
Alejandro Marmolejo-Garza
MTMarina Trombetta-Lima
Marina Trombetta-Lima
AOAsmaa Oun
Asmaa Oun
JHJasmijn Hunneman
Jasmijn Hunneman
ADAmalia Dolga
Amalia Dolga
Metabolic reprogramming is a hallmark of the immune cells in response to inflammatory stimuli. This metabolic process involves a switch from oxidative phosphorylation (OXPHOS) to glycolysis or alterations in other metabolic pathways. However, most of the experimental findings have been acquired in murine immune cells, and little is known about the metabolic reprogramming of human microglia. In this study, we investigate the transcriptomic, proteomic, and metabolic profiles of mouse and iPSC-derived human microglia challenged with the TLR4 agonist LPS. We demonstrate that both species display a metabolic shift and an overall increased glycolytic gene signature in response to LPS treatment. The metabolic reprogramming is characterized by the upregulation of hexokinases in mouse microglia and phosphofructokinases in human microglia. This study provides a direct comparison of metabolism between mouse and human microglia, highlighting the species-specific pathways involved in immunometabolism and the importance of considering these differences in translational research.

29 June 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GGGiambattista Guaitoli
Giambattista Guaitoli
FRFrancesco Raimondi
Francesco Raimondi
BGBernd K. Gilsbach
Bernd K. Gilsbach
YGYacob Gómez-Llorente
Yacob Gómez-Llorente
EDEgon Deyaert
Egon Deyaert
CGChristian Johannes Gloeckner
Christian Johannes Gloeckner
Significance: Leucine-rich repeat kinase 2 (LRRK2) represents a promising drug target for treatment and prevention of Parkinson’s disease (PD), because mutations in LRRK2 are the most common cause of Mendelian forms of the disease. PD-associated LRRK2 variants show decreased GTPase and increased kinase activity. By integrating multiple experimental inputs provided by chemical cross-linking, small-angle X-ray scattering, and a negative-stain EM map, we present, to our knowledge, the first structural model of the full-length LRRK2 dimer. The model reveals a compact folding of the LRRK2 dimer with multiple domain–domain interactions that might be involved in the regulation of LRRK2 enzymatic properties.

24 July 2008 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
KGKatja Gotthardt
Katja Gotthardt
MWMichael Weyand
Michael Weyand
Arjan KortholtArjan Kortholt
Arjan Kortholt
PHPeter J M Van Haastert
Peter J M Van Haastert
AWAlfred Wittinghofer
Alfred Wittinghofer
Ras of complex proteins (Roc) belongs to the superfamily of Ras‐related small G‐proteins that always occurs in tandem with the C‐terminal of Roc (COR) domain. This Roc–COR tandem is found in the bacterial and eukaryotic world. Its most prominent member is the leucine‐rich repeat kinase LRRK2, which is mutated and activated in Parkinson patients. Here, we investigated biochemically and structurally the Roco protein from Chlorobium tepidum . We show that Roc is highly homologous to Ras, whereas the COR domain is a dimerisation device. The juxtaposition of the G‐domains and mutational analysis suggest that the Roc GTPase reaction is stimulated and/or regulated by dimerisation in a nucleotide‐dependent manner. The region most conserved between bacteria and man is the interface between Roc and COR, where single‐point Parkinson mutations of the Roc and COR domains are in close proximity. The analogous mutations in C. tepidum Roc–COR decrease the GTPase reaction rate, most likely due to a modification of the interaction between the Roc and COR domains.

1 October 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
AGAngelica Maria Sabogal Guaqueta
Angelica Maria Sabogal Guaqueta
FHFabian Hobbie
Fabian Hobbie
AKAkshaya Keerthi
Akshaya Keerthi
AOAsmaa Oun
Asmaa Oun
Arjan KortholtArjan Kortholt
Arjan Kortholt
ADAmalia Dolga
Amalia Dolga
Mitochondrial dysfunction and inflammation contribute to the initiation and development of several brain pathological conditions, including Alzheimer's disease and cerebral ischemia. Linalool is an aromatic plant-derived monoterpene alcohol with reported anti-inflammatory, and anti-oxidant properties. We investigated the role of linalool on glutamate-induced mitochondrial oxidative stress in immortalized neuronal HT-22 cells. Glutamate induced oxidative stress in neuronal cells, as detected by real-time cell impedance measurements, MTT assay, and analysis of Annexin V/PI. Administration of linalool 100 μM reduced cell death mediated by glutamate. Staining of glutamate-stimulated mitochondria by MitoTracker revealed improved morphology in the presence of linalool. Furthermore, we demonstrated a potential neuroprotective effect of linalool in conditions of oxidative stress by a reduction of mitochondrial ROS and mitochondrial calcium levels, and by preserving mitochondrial membrane potential. Experiments using both high-resolution respirometry and Seahorse Extracellular flux analyzer showed that linalool was able to promote an increase in uncoupled respiration that could contribute to its neuroprotective capacity. Linalool protection was validated using organotypic hippocampal slices as ex vivo model with NMDA as a stimulus to induce excitotoxity cell damage. These results demonstrate that linalool is protective in an in vitro model of glutamate-induced oxidative stress and in an ex-vivo model for excitotoxity, proposing linalool as a potential therapeutic agent against neurodegenerative brain diseases where oxidative stress contributes to the pathology of the disease.

29 May 2007 in Journal of Cell Biology
Verified
Journal Article
Open access
PHPeter Van Haastert
Peter Van Haastert
IKIneke Keizer-Gunnink
Ineke Keizer-Gunnink
Arjan KortholtArjan Kortholt
Arjan Kortholt
Chemotaxis toward different cyclic adenosine monophosphate (cAMP) concentrations was tested in Dictyostelium discoideum cell lines with deletion of specific genes together with drugs to inhibit one or all combinations of the second-messenger systems PI3-kinase, phospholipase C (PLC), phospholipase A2 (PLA2), and cytosolic Ca2+. The results show that inhibition of either PI3-kinase or PLA2 inhibits chemotaxis in shallow cAMP gradients, whereas both enzymes must be inhibited to prevent chemotaxis in steep cAMP gradients, suggesting that PI3-kinase and PLA2 are two redundant mediators of chemotaxis. Mutant cells lacking PLC activity have normal chemotaxis; however, additional inhibition of PLA2 completely blocks chemotaxis, whereas inhibition of PI3-kinase has no effect, suggesting that all chemotaxis in plc-null cells is mediated by PLA2. Cells with deletion of the IP3 receptor have the opposite phenotype: chemotaxis is completely dependent on PI3-kinase and insensitive to PLA2 inhibitors. This suggest that PI3-kinase–mediated chemotaxis is regulated by PLC, probably through controlling PIP2 levels and phosphatase and tensin homologue (PTEN) activity, whereas chemotaxis mediated by PLA2 appears to be controlled by intracellular Ca2+.

1 February 2013 in European Journal of Cell Biology
Verified
Journal Article
Closed access
Annette Müller-TaubenbergerAnnette Müller-Taubenberger
Annette Müller-Taubenberger
Arjan KortholtArjan Kortholt
Arjan Kortholt
Ludwig EichingerLudwig Eichinger
Ludwig Eichinger